The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

@article{Corne1997TheEO,
  title={The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.},
  author={J. Corne and R. Djukanovi{\'c} and L. Thomas and J. Warner and L. Botta and B. Grandordy and D. Gygax and C. Heusser and F. Patalano and W. Richardson and E. Kilchherr and T. Staehelin and F. Davis and W. Gordon and L. Sun and R. Liou and G. Wang and T. Chang and S. Holgate},
  journal={The Journal of clinical investigation},
  year={1997},
  volume={99 5},
  pages={
          879-87
        }
}
CGP 51901 is a non-anaphylactogenic mouse/human chimeric anti-human IgE antibody that binds to free IgE and surface IgE of IgE-expressing B cells but not to IgE bound to high affinity IgE receptors (Fc epsilonR1) on mast cells and basophils or low affinity IgE receptors (Fc epsilonR2) on other cells. A phase 1 double-blind, placebo-controlled, single dose study with doses of 3, 10, 30, and 100 mg of CGP 51901 was conducted in 33 pollen-sensitive subjects who had raised levels of serum IgE and… Expand
Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti‐immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis
TLDR
The efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, a recombinant monoclonal mouse—human chimeric anti‐human immunoglobulin E (IgE) antibody were evaluated for patients with seasonal allergic rhinitis and a sustained 85% or greater reduction of serum free IgE levels was shown to be effective in improving clinical symptoms. Expand
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
TLDR
Anti-IgE appears to provide a prophylactic and therapeutic option for moderate to severe cases of many allergic diseases and conditions in which IgE plays a significant role and has potential for use to combine with specific and rush immunotherapy for increased safety and efficacy. Expand
Effect of anti-IgE therapy in patients with peanut allergy.
TLDR
A 450-mg dose of TNX-901 significantly and substantially increased the threshold of sensitivity to peanut on oral food challenge from a level equal to approximately half a peanut to one equal to almost nine peanuts, an effect that should translate into protection against most unintended ingestions of peanuts. Expand
Inhibition of human airway sensitization by a novel monoclonal anti-IgE antibody, 17-9.
TLDR
It is concluded that allergen responses in sensitized human airways are dependent on IgE levels in the sensitizing serum while nonspecific (hyper)responsiveness depends on serum factors other than IgE. Expand
The pharmacological basis of anti-IgE therapy
  • T. Chang
  • Medicine
  • Nature Biotechnology
  • 2000
TLDR
The structural basis of the specificity of the anti-IgE antibodies and pertinent results from in vitro experiments, animal model studies, and human clinical trials are analyzed in an attempt to provide a cogent pharmacological interpretation of the therapeutic effects of anti- IgE therapy in both the near- and long term. Expand
Therapeutic potential of anti-IgE antibodies.
TLDR
In mice these antibodies selectively reduce serum IgE, inhibit antigen induced skin reactions, cytokine production by lung Th2 cells, and pulmonary eosinophil infiltration, and clinical trials in humans reveal that such antibodies are well tolerated and reduce rhinitis symptoms and early and late phase bronchoconstriction responses. Expand
Quantitation of serum IgE by using chimeras of human IgE receptor and avian immunoglobulin domains.
TLDR
An analytical approach to distinguish free and anti-IgE complexed serum IgE based on soluble derivatives of the human high-affinity IgE receptor found the FcεRI ectodomain was fused with avian IgY constant domains that circumvent susceptibility to interference phenomena and improve assay performance. Expand
Recombinant soluble form of the high-affinity IgE receptor α subunit and anti-IgE antibody inhibit IgE synthesis by IgE-expressing B cells through distinct pathways
TLDR
Results indicate that regulation of IgE synthesis by rsFceRIα differs from that by anti-IgE antibody, and the addition of IL-6 to cultures containing rsFcesRIα significantly restored its suppressive effect on IgEhesis. Expand
Innovative therapies for asthma: anti-IgE -- the future?
TLDR
Since IgE causes disease by the antigenic bridging of IgE molecules on the mast cell with the consequent release of various mediators including histamine and leukotrienes, these investigators concluded that this could result in an antiIgE such as they had studied being a candidate for immunotherapy of Ig E mediated disease. Expand
Anti-IgE Agents
TLDR
The development of drugs that interfere with IgE production and function may represent a more specific approach to treat these pathological conditions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy.
TLDR
IgE antibody measurements may be useful in the assessment of the severity of reaginic allergy in highly sensitive patients and the inverse association between IgE and IgG antiragweed antibodies requires further study. Expand
Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody
TLDR
It is demonstrated that IgE-dependent mechanisms are important in the induction of a Th2 immune response and the subsequent infiltration of eosinophils into the airways and neutralization of IgE, for example, non- anaphylactogenic anti-IgE mAbs may provide a novel therapeutic approach to the treatment of allergic airway disease. Expand
Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies.
TLDR
The studies support the benefits of intranasal steroids in the treatment of seasonal allergic rhinitis and suggest that specific IgE production may be down-regulated by their continuous use, which may alter the subsequent clinical course of the disease. Expand
The mast cell binding site on human immunoglobulin E
TLDR
The mapping of the mast cell receptor binding site on human IgE to a sequence of 76 amino acids at the Cɛ2/Cɛ 3 junction is reported, suggesting that a single chain can form the active site. Expand
IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells.
TLDR
It is confirmed that mast cells, and not T cells, were the source of these cytokine messages by using reverse transcriptase-PCR in cell preparations containing known numbers of mast cells and T Cells, in situ hybridization in enriched mast cell preparations, and double in situ Hybridization-immunocytochemical staining. Expand
Association of asthma with serum IgE levels and skin-test reactivity to allergens.
TLDR
It is concluded that asthma is almost always associated with some type of IgE-related reaction and therefore has an allergic basis, although not all the allergic stimuli that cause asthma appear to have been included in the battery of common aeroallergens the authors used to assess atopic status. Expand
Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.
TLDR
The human immunoglobulin G4 isotype chimeric B72.3 monoclonal antibody has a plasma half-life 6 to 8 times as long as murine B 72.3 and retains considerable immunogenicity in some patients which can adversely affect repetitive infusions. Expand
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
TLDR
This chimeric form of 17-1A mAb has an approximate 6-fold longer circulation time and appears to be substantially less immunogenic than its murine counterpart, which may provide an advantage in the clinical application of such chimeric molecules in therapeutic trials in humans. Expand
IgE‐dependent antigen focusing by human B lymphocytes is mediated by the low‐affinity receptor for IgE
TLDR
The results indicate a new role of the FcϵRII/CD23 molecules in the uptake of antigen by APC which might be of importance in the maintenance of an ongoing immune response against allergens. Expand
Functional analysis of a T cell line specific for antiidiotypic antibodies to a Schistosoma mansoni protective epitope. II. Induction of protective immunity in experimental rat schistosomiasis.
TLDR
The data suggest that the protective immunity induced by the anti-Ab2 cells is supported both by the cellular and humoral components and that in a future vaccinating strategy the idiotypic network may play a crucial role. Expand
...
1
2
3
4
5
...